title: Management of hemolytic uremic syndrome.
abstract: 2011 has been a special year for hemolytic uremic syndrome (HUS): on the one hand, the dramatic epidemic of Shiga toxin producing E. coli -associated HUS in Germany brought the disease to the attention of the general population, on the other hand it has been the year when eculizumab, the first complement blocker available for clinical practice, was demonstrated as the potential new standard of care for atypical HUS. Here we review the therapeutic options presently available for the various forms of hemolytic uremic syndrome and show how recent knowledge has changed the therapeutic approach and prognosis of atypical HUS.
authors.affiliation: Assistance publique-Hôpitaux de Paris, Hôpital Robert-Debré, Nephrology Department, 75019 Paris, France. chantal.loirat@rdb.aphp.fr
authors.forename: Chantal
authors.initials: C
authors.lastname: Loirat
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Saland
authors.forename: Martin
authors.initials: M
authors.lastname: Bitzan
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy; D000465:Algorithms; D000592:Amino Acid Metabolism, Inborn Errors / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D065766:Atypical Hemolytic Uremic Syndrome; D001810:Blood Volume; D002648:Child; D004232:Diuretics / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005858:Germany / Q000453:epidemiology; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D006712:Homocystinuria / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D016030:Kidney Transplantation; D010949:Plasma / Q000276:immunology; D010951:Plasma Exchange / Q000379:methods; D010956:Plasmapheresis; D011008:Pneumococcal Infections / Q000150:complications; D011379:Prognosis; D006435:Renal Dialysis; D022603:Shiga Toxins / Q000276:immunology / Q000633:toxicity; D054323:Shiga-Toxigenic Escherichia coli; D013296:Streptococcus pneumoniae; D014806:Vitamin B 12 Deficiency / Q000151:congenital; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004232:Diuretics; D005343:Fibrinolytic Agents; D022603:Shiga Toxins; C481642:eculizumab